TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Story updates
08:12:02 PM UTC
SquawkNews
Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma-Early clin…
08:12:43 PM UTC
SquawkNews
Tempest signed an exclusive option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including a BCMA/GPRC5D candidate in Phase 1 dose escalation with early in vivo CAR-T generation and no Grade ≥3 CRS or ICANS reported to date.Material DetailsContext by AI AnalystThis is an earl…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.